"Daiichi Sankyo has funded the progression of Laninamivir through the Japanese approval process and currently has a treatment indication there. It also has an application to the Japanese regulators for a prophylaxis indication, crucial for the governmental stockpiling market. Biota currently receives a 4% royalty for Inavir increasing to 6% when Laninamivir is approved in the rest of the world."
Maybe I am reading this wrong - so happy to hear others' interpretations - but what does the "...increasing to 6% when Laninamivir is approved in the rest of world" mean??
Not that Biota will receive a 6% royalty on ROW sales, surely?
What am I missing here?
"Daiichi Sankyo has funded the progression of Laninamivir...
-
- There are more pages in this discussion • 16 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)